Physician profile
Howard A Green
NPI 1053301655
$4,777.02
in general payments reported to CMS, 2019-2025
31 companies · $845 in 2025
The $845 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $478 · 2020: $410 · 2021: $767 · 2022: $589 · 2023: $779 · 2024: $909 · 2025: $845.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,373 · Education: $159.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,373.32 |
| Education | $159.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $836.50 | 2019-2025 | |
| Incyte Corporation | $496.09 | 2021-2025 | Opzelura |
| Novartis Pharmaceuticals Corporation | $379.13 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $331.04 | 2023-2025 | Spevigo |
| Ucb, INC. | $311.89 | 2020-2025 | Bimzelx, Cimzia |
| Prugen, INC. Pharmaceuticals | $289.84 | 2019 | |
| Organogenesis INC. | $284.73 | 2019-2025 | Affinity |
| Sun Pharmaceutical Industries INC. | $271.52 | 2019-2024 | Ilumya |
| Leo Pharma INC. | $268.07 | 2020-2025 | Adbry, Spevigo, Anzupgo |
| Pfizer INC. | $215.26 | 2021-2025 | |
| Lilly USA, LLC | $171.20 | 2020-2025 | Ebglyss, Taltz, Olumiant |
| Kerecis Limited | $131.27 | 2024-2025 | Kerecis Omega3 Marigen, Kerecis Surgiclose, Kerecis Omega3 Surgiclose |
| E.R. Squibb & Sons, L.L.C. | $106.87 | 2023-2025 | Sotyktu |
| Janssen Biotech, INC. | $103.80 | 2020-2023 | Tremfya |
| Regeneron Healthcare Solutions, INC. | $75.83 | 2021-2025 | Libtayo |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $67.58 | 2020-2022 | |
| Inspire Medical Systems, INC. | $65.37 | 2023-2025 | Inspire |
| Vyne Pharmaceuticals INC. | $58.49 | 2020-2021 | |
| Almirall LLC | $49.53 | 2021-2025 | Klisyri |
| Biofrontera INC. | $36.63 | 2021-2022 | |
| Tactile Systems Technology INC | $30.73 | 2020-2024 | Flexitouch Plus, Entre Plus |
| Helsinn Therapeutics (U.S.), INC. | $28.89 | 2020-2022 | |
| Strata Skin Sciences, INC. | $27.74 | 2024 | Xtrac |
| Dermavant Sciences, INC. | $23.87 | 2023 | Vtama |
| Galderma Laboratories, L.P. | $21.98 | 2025 | Nemluvio |
| Botanix Sb INC | $19.10 | 2025 | Sofdra |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $15.71 | 2019 | |
| Organon LLC | $15.07 | 2025 | Hadlima |
| Allergan, INC. | $14.95 | 2019 | |
| Arcutis Biotherapeutics, INC. | $14.29 | 2023 | |
| Mimedx Group, INC. | $14.05 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Howard Green listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.